Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Sezary Syndrome 1Recurrence 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Large-Cell, Anaplastic 1Leukemia, Myeloid, Acute 1

Interventions

Cyclophosphamide 9Biopsy 5Specimen Handling 4Prednisone 4Nivolumab 4Magnetic Resonance Spectroscopy 4fludarabine 3Vincristine 3Etoposide 3Doxorubicin 3Brentuximab Vedotin 3sodium-iodide symporter 2pembrolizumab 2fludarabine phosphate 2cemiplimab 2alectinib 2X-Rays 2Whole-Body Irradiation 2Stem Cell Transplantation 2Rituximab 2Positron-Emission Tomography 2Photons 2Mycophenolic Acid 2Immunoglobulin G 2Filgrastim 2Disulfides 2Cyclosporine 210-propargyl-10-deazaaminopterin 2treosulfan 1talimogene laherparepvec 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphoma, Large-Cell, Anaplastic × Aclarubicin × 1 year × Clear all
NCT07535762 2026-04-17

Aclarubicin Plus Cyclophosphamide, Vincristine, and Prednisone (CAOP) in Patients With Previously Untreated Peripheral T-Cell Lymphoma

Shanghai Jiao Tong University School of Medicine

Phase 2 Not yet recruiting
36 enrolled
Lymphoid

Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡